{"denomUnitsSelected":"Participants","description":"Will be assessed by IgH somatic hypermutation assay version 2.0. Will associate with response (ORR) to entospletinib (ENTO) in combination with obinutuzumab in patients with relapsed/refractory CLL.","reportingStatus":"NOT_POSTED","timeFrame":"Up to 45 months","title":"Biomarkers (Chromosomal Abnormalities, IGHV Mutational Status, p53 Mutational Status)","type":"OTHER_PRE_SPECIFIED"}